Live Breaking News & Updates on காப்ஸ்யூல்

Stay updated with breaking news from காப்ஸ்யூல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Welcome To IANS Live - INTERNATIONAL - People bid over $2mn for first ride on Blue Origin's spaceship


Photo Credit: IANS
IANSLive
Washington, May 21 (IANS) People are bidding as high as $2.8 million for a 10-minute experience on Amazon founder Jeff Bezos s aerospace company Blue Origin s space tourism mission New Shepard, the media reported.
To get full access of the story, click here to subscribe to IANS News Service
© 2021 IANS India Private Limited. All Rights Reserved.
The reproduction of the story/photograph in any form will be liable for legal action.
For news, views and gossips, follow IANS at Twitter.
Update: 21-May-2021 ....

United States , Jeff Bezos , Blue Origin , News Service , India Private , New Shepard , All Rights , ஒன்றுபட்டது மாநிலங்களில் , நீலம் ஆரிஜிந் , செய்தி சேவை , இந்தியா ப்ரைவேட் , புதியது ஷெப்பர்ட் , அனைத்தும் உரிமைகள் ,

Welcome To IANS Live - SCIENCE - People bid over $2mn for first ride on Blue Origin's spaceship


Photo Credit: IANS
IANSLive
Washington, May 21 (IANS) People are bidding as high as $2.8 million for a 10-minute experience on Amazon founder Jeff Bezos s aerospace company Blue Origin s space tourism mission New Shepard, the media reported.
To get full access of the story, click here to subscribe to IANS News Service
© 2021 IANS India Private Limited. All Rights Reserved.
The reproduction of the story/photograph in any form will be liable for legal action.
For news, views and gossips, follow IANS at Twitter.
Update: 21-May-2021 ....

United States , Jeff Bezos , Blue Origin , News Service , India Private , New Shepard , All Rights , ஒன்றுபட்டது மாநிலங்களில் , நீலம் ஆரிஜிந் , செய்தி சேவை , இந்தியா ப்ரைவேட் , புதியது ஷெப்பர்ட் , அனைத்தும் உரிமைகள் ,

Covid treatment: Optimus Pharma gets DCGI nod for phase 3 trials of Molnupiravir


May 19, 2021
The orally administered drug is being tested for treating mild and moderate infection
Optimus Pharma has received the approval of the Drug Controller General of India (DCGI) to conduct Phase III clinical trials of orally administered Molnupiravir capsules on patients with mild and moderate Covid-19 infection.
As per the clinical trial protocols approved, a total of 2,500 subjects in both mild and moderate Covid-19 will be randomised in the study in a 1:1 ratio to Molnupiravir with standard supportive care or standalone standard supportive care.
Treatment modes
The treatment duration is a maximum of five days and the total study duration will be maximum for 29 days from randomisation, the Hyderabad-based company said in a release on Wednesday. ....

Andhra Pradesh , Drd Srinivas Reddy , Optimus Pharma , Drug Controller General , Srinivas Reddy , Managing Director , Covid 19 , Dcgi Nod , Phase 3 Trials , ஆந்திரா பிரதேஷ் , ட ஸ்ரீநிவாஸ் சிவப்பு , உகந்த பார்மா , மருந்து கட்டுப்படுத்தி ஜநரல் , ஸ்ரீநிவாஸ் சிவப்பு , நிர்வகித்தல் இயக்குனர் , சர்வதேச பரவல் , கட்டம் சோதனைகள் ,